“..we took them to the deep end of the pool where they couldn’t swim..”
…drs david lewis, md and christopher russo.md
youarewithinthenorms.com
NORMAN J CLEMENT RPH., DDS, NORMAN L. CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC., SPIRIT OF REV. IN THE SPIRIT OF WALTER R. CLEMENT BS., MS, MBA. HARVEY JENKINS, MD, PH.D., IN THE SPIRIT OF C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., M.B.A., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., EVELYN J. CLEMENT, IN THE SPIRIT OF WALTER F. WRENN III., MD., JULIE KILLINGSWORTH, RENEE BLARE, RPH, DR. TERENCE SASAKI, MD LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, IN THE SPIRIT OF WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., RICHARD KAUL, MD., IN THE SPIRIT OF LEROY BAYLOR, JAY K. JOSHI MD., MBA, AISHA GARDNER, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS
🕷️🕷️🕷️
Introduction:
Shifting the Perspective on Addiction
In the realm of clinical medical science, we must move past the reductive and unscientific metrics that have dominated addiction discourse.
For too long, the “missing link” in treating opiate use disorder has been the reliance on Morphine Milligram Equivalents (MME)—a metric that provides a false sense of precision while ignoring the fundamental biological realities of drug absorption, receptor affinity, and liver metabolism.
To treat addiction effectively, we must stop viewing it through the lens of social stigma or simple arithmetic myths and start addressing the physiological processes of the human body.
Ken Pettingil, a chronic pain patient who is currently preparing an opposition to a motion to dismiss in a federal case concerning access to medical care under the Americans with Disabilities Act and Section 504 of the Rehabilitation Act.
The case involves questions of whether systemic constraints on individualized treatment can result in meaningful functional impairment for patients with severe chronic pain.
Key Insight: Understanding physiology is as vital for treating addiction as it is for treating diabetes.
Just as we do not manage blood sugar through “dose-dependency” myths but through a rigorous understanding of insulin and glucose metabolism, we must apply the same clinical rigor to the biology of opiates.
The failure to recognize that addiction is a biological process rather than a mere behavioral choice has led to the tyranny of unscientific prescribing limits.
By shifting our perspective to the microscopic sites where these drugs interact with the nervous system, we can align our clinical practice with reality.
——————————————————————————–
The Gateway:
How Opiate Receptors Function
Opiate receptors are the primary targets for medications, serving as the gateway to both stabilization and recovery. Within this system, the Mu receptor is the critical site of action. However, the interaction is more complex than a simple “on/off” switch. It involves distinct phases of activation.
Suboxone (buprenorphine/naloxone) is engineered to interact with these receptors as a partial agonist/antagonist, ensuring that the physiological need is met without triggering the destructive phases of receptor activation.
| Receptor Interaction | Effect on the Body |
| Mu Receptor Activation | Traditional opiates fully activate the receptor, triggering the specific phase responsible for the experience of euphoria (the “high”). |
| Mu Receptor Blockage | Suboxone attaches to the receptor to prevent other opiates from connecting; crucially, the euphoric phase of the Mu receptor is not activated during this process. |
While receptors are the final destination for these molecules, the liver acts as the engine that dictates the “bioavailability” or the actual amount of medication that reaches these sites.
——————————————————————————–
The Engine:
Liver Detoxification and the “Missing Link”
A central question in clinical science is why patients require increasing doses to achieve stability. The answer lies in the liver’s metabolic rate of detoxification.
The liver is a dynamic organ that adapts to the presence of substances by accelerating its processing speed. This metabolic acceleration is the primary driver of dose requirements, a fact routinely ignored by MME-based guidelines.
Dr. Muhamad Aly Rifai’s article explores the growing trend of legal systems targeting medical professionals. In this critical examination of the American legal system, Dr. Muhamad Aly Rifai argues that the government has undergone a dangerous shift toward the criminalization of physician care, transforming healers into targets of aggressive federal pursuit.
Rifai’s work further highlights how complex medical decisions are increasingly misinterpreted as criminal intent, leading to an environment where prosecutorial overreach and a presumption of guilt devastate the lives of innocent practitioners.
Rifai’s work further highlights how complex medical decisions are increasingly misinterpreted as criminal intent, leading to an environment where prosecutorial overreach and a presumption of guilt devastate the lives of innocent practitioners.
By detailing the ruinous impact on both doctors and the patients they serve, the author illustrates how weaponized regulations and biased statistics force physicians into submission, regardless of their actual guilt.
The sequence of physiological events occurs as follows:
- Ingestion: The substance enters the systemic circulation.
- Metabolic Response: The liver identifies the substance and initiates detoxification.
- Increased Detoxification Rate: With repeated exposure, the liver’s metabolic engine becomes more efficient, breaking down the substance at an accelerated rate.
- Physiological Necessity of Higher Doses: Because the liver clears the drug more rapidly, higher doses than are presently prescribed are often a physiological necessity to maintain the plasma levels required to suppress cravings and withdrawal.
This understanding of the liver’s metabolic speed is exactly why medications like Suboxone must be processed and prescribed according to individual biology rather than arbitrary administrative norms.
——————————————————————————–
The Safety Valve:
Suboxone and the ‘Ceiling Effect’
Suboxone is a sophisticated pharmaceutical intervention designed to stabilize the patient’s internal chemistry while incorporating essential safety mechanisms. By combining two distinct components, it addresses both the physiological drive for opiates and the acute risk of respiratory depression.
| Component | Primary Function |
| Buprenorphine | A partial agonist that attaches firmly to receptors, blocking full-agonist opiates from binding and preventing the physical drive of addiction. |
| Naloxone | An antagonist included to prevent the overdose process, acting as a critical safety barrier. |
The “Ceiling Effect” is perhaps the most significant safety feature for the patient; it ensures that after a specific threshold is reached, the pharmacological effect plateaus.
This prevents the life-threatening respiratory depression associated with traditional opiates. These chemical functions are not merely “harm reduction” tools; they are the pillars of a successful medical treatment plan designed to restore the patient to homeostasis.
Clinical Synthesis:
Treating Addiction Like a Science
When we apply scientific rigor to addiction, we see that it mirrors the management of other chronic metabolic conditions like diabetes. Our success in diabetes care stems from targeting specific physiological failures:
- Metformin is utilized to prevent the liver from overproducing sugar between meals. It reduces glucose absorption from the intestines, lowers liver glucose production, and improves insulin sensitivity. Metformin is recommended with dietary changes and exercise for better results.
- Insulin is administered when the body’s beta cells can no longer meet physiological demands. Insulin is a hormone that is produced naturally in our bodies. Its main role is to enable cells throughout the body to take up glucose (sugar) and convert it into a form that can be used for energy. Naturally occurring human insulin is made by beta cells within the pancreas, but people with diabetes have little or no natural insulin release.
- SGLT2 inhibitors are used to excrete excess sugar in the urine, removing circulating glucose that has not been taken up by the mitochondria for energy. SGLT-2 inhibitors inhibit SGLT-2 proteins located in the renal tubules of the kidneys which are responsible for reabsorbing glucose back into the blood. As a result, more glucose is excreted in the urine. SGLT-2 inhibitors have been shown to be effective at lowering hemoglobin A1c levels, improving weight loss and lowering blood pressure. They carry a low risk of hypoglycemia (low blood sugarlevels).
The “So What?” of this comparison is clear: just as a diabetic requires specific doses to manage sugar, an addiction patient requires high enough plasma levels of buprenorphine to prevent the biological drive of cravings. Current prescribing norms often fall short of these clinical requirements because they ignore the metabolic engine of the liver.
Future Takeaways for Addiction Science:
- Physiological Reality: We must abandon the MME metric, which ignores drug absorption and receptor affinity, in favor of a model that prioritizes individual metabolic rates.
- Evidence-Based Processing: Clinical success depends on analyzing medications based on how they are actually “processed” by the body, rather than adhering to simple arithmetic myths.
- The Norms of Health: The ultimate goal of buprenorphine therapy is to maintain correct plasma levels so the patient can function “within the norms” of healthy, productive life.
By illuminating the biology behind addiction treatment, we transform the treatment of addiction from a misunderstood social issue into a precise and effective clinical discipline.
Dr. Rifia…. “struggle reveal that these agencies’ intrusions and overreaches are built on half-truths that support their foundation of Judicial Architectural Deception to imprison more medical providers with the utmost efficiency.”
🔓 🔓 🔓
ALL WATCHED OVER BY MACHINES OF LOVING GRACE
BE SURE TO DONATE TO THE MARK IBSEN GOFUNDME DEFENSE FUND, WHERE THE SON ALWAYS RISES!!!
OUR TREE OF KNOWLEDGE SHALL NEVER BE SUPPRESSED
FOR NOW, YOU ARE WITHIN
THE NORMS
REFERENCES:
THE D.E.A. INTERNAL COURT SYSTEM A TRIBUNAL OUTSIDE THE LAW
MEDICINE ON TRIAL
